IPO
-
Digital health funding smashed another record this year, but is the trend sustainable?
Digital health companies have now raised more than $20 billion in 2021, more than any other year. While experts expect to see the dealmaking continue, they raised caution about the challenges of going public with high valuations.
-
Better Therapeutics goes public through SPAC, will put proceeds toward first digital therapeutic
The startup is developing digital therapeutics that use cognitive behavioral therapy-based programs to address cardiometabolic conditions. It began trading on Nasdaq on Friday.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Health IT, Hospitals, Health Tech
With 5 patents under its belt, RCM tech company Ensemble Health Partners files for IPO
The company, which provides revenue cycle management solutions for providers, is filing for the IPO less than two years after Bon Secours Mercy Health sold its majority stake in Ensemble to private equity firm Golden Gate Capital. Per the filing, the company aims to raise $100 million, but that is likely a placeholder figure.
-
Portable diagnostics company Cue raises $200M in IPO
The diagnostics company currently has an authorized at-home Covid-19 test, and plans to expand into flu tests and other diagnostics. After pricing its stock at $16 per share, it climbed to $20 on Friday.
-
Buoyed by Covid-19 tests, Cue files for IPO
The San Diego-based company began marketing its first product, a portable Covid-19 test, after receiving an emergency use authorization last year. Now, it’s filing the initial paperwork to go public as it scales up manufacturing.
-
Bright Health to grow footprint in 2022, adding 42 new markets
Bright Health will use proceeds from its IPO to fund the expansion, which will bring its total number of markets to 141 from 99. The company will also expand its product portfolio in states where it already operates.
-
Denver-based direct primary care startup files to go public
Everside Health Group, a Denver-based direct primary care startup, filed to go public. The company was formed out of a merger between three primary care groups, and primarily works with self-insured employers.
-
Doximity’s stock doubles after IPO. Here’s how it plans to keep the momentum going.
The social network for physicians recently went public in an upsized IPO that valued the company at about $4.6 billion. With many physicians already on the platform, chief strategy officer Dr. Nate Gross shared the company’s plans for future growth.
-
Pear Therapeutics plans to go public in $1.6B SPAC deal
Digital therapeutics startup Pear Therapeutics struck a deal to go public through a blank-check acquisition that would value the company at $1.6B. But it still faces big challenges in selling its app-based treatments.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Bright Health sets terms for $1.3B IPO
With plans to sell 60 million shares of common stock, Bright Health will price its IPO between $20 and $23 per share. It will trade on the New York Stock Exchange under the symbol “BHG,” according to a recent SEC filing.
-
Bloom is off the health tech IPO rose, as valuations expected to fall
In Venrock’s annual survey of healthcare leaders, respondents expected most digital health startups that went public during the pandemic to see their valuations fall by the end of the year.
-
Bright Health follows rival Oscar Health down IPO path
Bright Health has filed preliminary paperwork for an IPO, joining its rivals in the insurance technology space in going public. Though there are few confirmed details at the moment, Bright Health is reportedly looking to raise $1 billion through the offering.
-
Wall Street is lukewarm to Vera’s pivot from gene editing to rare kidney disease
Vera Therapeutics raised $47.9 million from its IPO to continue clinical development of its lead asset, a potential treatment for the kidney disease IgA nephropathy. But the company is joining a crowded field of companies aiming to develop a drug for the rare disorder.
-
Privia Health CEO: IPO allows us to be independent & purely focused on strategy
In a wide-ranging interview, Privia Health CEO Shawn Morris discussed the company’s recently closed IPO, its plans for the funds raised and what he sees as the company’s biggest value-add as the Covid-19 pandemic enters a new phase.